Search NLS News

The company has received a substantial investment from Kempestiftelserna.

This year in Malmö two awards in two different competitions were handed out, the Nordic Star pitch competition and the Innovation Poster exhibition.

For seriously ill children and adolescents, intravenous drip stands can significantly hinder mobility.

A new bioanalytical laboratory, creating up to 140 new jobs for researchers and laboratory staff, will be established during the last quarter of 2025.

Anocca will present its novel platform approach to therapeutic TCR discovery and preclinical data for its lead TCR-T cell therapy product at the European Society of Medical Oncology (ESMO) Congress 2024.

The results further demonstrate the potential for TILT-123 as an intravenous therapy.

The company has agreed with the investigators conducting the LUNGVAC trial to discontinue patient recruitment.

Medivir has presented positive, mature data from its ongoing phase 1b / 2a study of fostroxacitabine bralpamide (fostrox) + Lenvima in advanced liver cancer at the ESMO Congress in Barcelona, Spain.

Navamedic has partnered with Alex Therapeutics to aid in Parkinson’s treatment management.

Oncopeptides has announced that it has signed an exclusive license and supply agreement with SCBIO, a Korean pharmaceutical company for the commercialization of Oncopeptides’ flagship drug Pepaxti in South Korea.